[HTML][HTML] A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
Haematologica, 2012•ncbi.nlm.nih.gov
Background Mantle cell lymphoma accounts for 6% of all B-cell lymphomas and is generally
incurable. It is characterized by the translocation t (11; 14) leading to cyclin D1 over-
expression. Cyclin D1 is downstream of the mammalian target of rapamycin threonine
kinase and can be effectively blocked by mammalian target of rapamycin inhibitors. We set
out to examine the single agent activity of the orally available mammalian target of
rapamycin inhibitor everolimus in a prospective, multicenter trial in patients with relapsed or …
incurable. It is characterized by the translocation t (11; 14) leading to cyclin D1 over-
expression. Cyclin D1 is downstream of the mammalian target of rapamycin threonine
kinase and can be effectively blocked by mammalian target of rapamycin inhibitors. We set
out to examine the single agent activity of the orally available mammalian target of
rapamycin inhibitor everolimus in a prospective, multicenter trial in patients with relapsed or …
Abstract
Background
Mantle cell lymphoma accounts for 6% of all B-cell lymphomas and is generally incurable. It is characterized by the translocation t (11; 14) leading to cyclin D1 over-expression. Cyclin D1 is downstream of the mammalian target of rapamycin threonine kinase and can be effectively blocked by mammalian target of rapamycin inhibitors. We set out to examine the single agent activity of the orally available mammalian target of rapamycin inhibitor everolimus in a prospective, multicenter trial in patients with relapsed or refractory mantle cell lymphoma (NCT00516412
ncbi.nlm.nih.gov